MAAQ SEC filings, in plain English
Everything Mana Capital Acquisition Corp. has filed with the SEC that we hold — 40 filings, newest first, 6 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Cardio Diagnostics Holdings (post-merger entity from MAAQ) filed an investor presentation detailing commercial progress including CMS final payment rate of $854/test (Dec 2025), first in-network coverage via Atlas Healthcare Physicians (June 2026), out-of-network billing capability (July 2026), and in-house CLIA lab operations reducing COGS ~30%. Why it matters: The presentation signals meaningful reimbursement and commercialization milestones for the de-SPAC company, with Medicare coverage determination and commercial payer pilots still in progress—key drivers for revenue ramp and the ~$175B combined TAM.
What changed: DEFA14A of Cardio Diagnostics Holdings, Inc. — definitive additional proxy materials filed August 7, 2026. The captured document consists of the Schedule 14A cover page identifying the registrant, the 'Definitive Additional Materials' box and the fee statement ('No fee required'); no substantive soliciting content appears in the text available here. Why it matters: Nothing can be read from this document about what was communicated to stockholders — the accompanying material is not part of the captured text, so the filing establishes only that additional proxy materials were filed on that date.(flagged for human review)
What changed: Q2 2026 10-Q of Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO). As of August 7, 2026 there were 2,959,469 shares of common stock outstanding. The introductory note states the company effected a 1-for-30 reverse stock split effective May 12, 2025, and that all issued and outstanding stock and per-share amounts in the report, together with the exercise prices and share numbers under its equity incentive plans and outstanding warrants, have been adjusted for that split for all prior periods presented. Why it matters: All per-share history in this report is restated for the 1-for-30 split, so nothing here is comparable to figures published before May 2025 on a pre-split basis. This summary is drawn from the cover page and introductory notes; the financial statements are not covered here.
What changed: Cardio Diagnostics Holdings, Inc. (the post-merger entity from Mana Capital Acquisition Corp.) filed a DEF 14A for its 2026 annual meeting on September 18, 2026, with a record date of July 31, 2026 and 2,959,469 shares outstanding. The proxy includes a proposal (No. 2) to approve the future issuance of shares equal to 20% or more of outstanding common stock in a non-public transaction to raise up to $10.0 million, consistent with similar proposals approved at the 2023, 2024, and 2025 annual meetings but never utilized. Why it matters: This filing confirms the post-merger company is operational and seeking continued shareholder authorization for potential dilutive capital raises, though it has relied on an ATM facility since early 2024. For SPAC trackers, it signals the de-SPAC entity is navigating ongoing capital needs and Nasdaq listing compliance rather than any new trust, extension, or redemption event.
What changed: Cardio Diagnostics Holdings, Inc., the Mana Capital Acquisition Corp. successor, filed a preliminary proxy for a virtual annual meeting on Friday, September 18, 2026 at 11:00 a.m. Central Time, with a July 31, 2026 record date and a notice of internet availability to be mailed on or about August 7, 2026. Among the proposals is approval under Nasdaq Rule 5635(d) of issuing securities convertible into or exercisable for common stock equal to 20% or more of the shares outstanding in a non-public transaction or series of transactions. Similar approvals were sought in 2023 and 2024. Why it matters: Seeking the same Nasdaq 20% authorisation for a third consecutive year tells a holder how this company funds itself: through repeated private issuances of convertible securities, each requiring shareholder consent because each exceeds a fifth of the share count. Approval hands management standing authority to issue below market in non-public transactions, and the cumulative effect across three such authorisations is the dilution former MAAQ holders have absorbed. Being preliminary, the terms may change before the definitive proxy.
- What changed vs 2025-03-20mandate language changed
mandate language1 moved
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Cardio Diagnostics Holdings, Inc., the successor to Mana Capital Acquisition Corp., called its annual meeting for Wednesday, October 15, 2025 at 10:00 a.m. Central Time as a completely virtual meeting, record date August 25, 2025, with the Notice of Internet Availability mailed on or about September 4, 2025. Holders are asked to approve, under Nasdaq Marketplace Listing Rule 5635(d), the issuance of securities convertible into or exercisable for common stock equal to 20% or more of outstanding common stock in a non-public transaction or series of transactions. Why it matters: This is the third consecutive annual meeting at which holders have been asked to lift the Nasdaq 20% cap for private placements - the company has made serial dilution an annual governance ritual rather than a one-off financing event. Each approval covers a fresh series of transactions, so the cumulative issuance across three years is far larger than any single vote suggests. The Mana Capital trust was released at the de-SPAC.
What changed vs 2024-10-04going concern RESOLVEDgoing-concern doubt1 moved
- Going-concern doubt
- statednot stated
SpacBrain reads this as the substantial-doubt sentence is in the previous filing and not in this one.
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.